Allan Gibofsky, MD

Industry Relationships

One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.

As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.

Below are the healthcare industry relationships reported by Dr. Gibofsky as of June 05, 2019.

• AbbVie Inc. -Advisory Board; Consultant; Ownership Interest; Speakers' Bureau
• Celgene - Advisory Board; Consultant; Speakers' Bureau
• Gilead Sciences, Inc.- Consultant
• Horizon Therapeutics - Consultant
• Johnson & Johnson- Ownership Interest
• Lilly- Consultant
• Merck- Advisory Board; Speakers' Bureau
• Novartis- Speakers' Bureau
• Pfizer, Inc. - Author; Advisory Board; Consultant; Honoraria; Ownership Interest; Speakers' Bureau
• Relburn Pharmaceuticals - Advisory Board
• Sandoz- Consultant
• Takeda Pharmaceuticals - Consultant
• Up-to- Date- Author
• US Food and Drug Administration- Consultant

By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.

Patients should feel free to ask their HSS physicians questions about these relationships.